Escherichia coli –Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer
Open accessPublished version of a preprint
The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Abstract
Biomarkers guiding the neoadjuvant use of immune-checkpoint blockers (ICB) are needed for patients with localized muscle-invasive bladder cancers (MIBC). Profiling tumor and blood samples, we found that follicular helper CD4+ T cells (TFH) are among the best therapeutic targets of pembrolizumab correlating with progression-free survival. TFH were associated with tumoral CD8 and PD-L1 expression at baseline and the induction of tertiary lymphoid structures after pembrolizumab. Blood central memory TFH accumulated in tumors where they produce CXCL13, a chemokine found in the plasma of responders only. IgG4+CD38+ TFH residing in bladder tissues correlated with clinical benefit. Finally, TFH and IgG directed against urothelium-invasive Escherichia coli dictated clinical responses to pembrolizumab in three independent cohorts. The links between tumor infection and success of ICB immunomodulation should be prospectively assessed at a larger scale. SIGNIFICANCE: In patients with bladder cancer treated with neoadjuvant pembrolizumab, E. coli-specific CXCL13 producing TFH and IgG constitute biomarkers that predict clinical benefit. Beyond its role as a biomarker, such immune responses against E. coli might be harnessed for future therapeutic strategies. This article is highlighted in the In This Issue feature, p. 2221.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
2 retracted
Dubourg, G., Morand, A., Mekhalif, F., Godefroy, R., Corthier, A., Yacouba, A., Diakite, A., Cornu, F., Cresci, M., Brahimi, S., et al. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.513305 · Cited by 66
RetractedRETRACTED ARTICLE: Tobacco-smoking-related prevalence of methanogens in the oral fluid microbiota
Grine, G., Terrer, E., Boualam, M. A., Aboudharam, G., Chaudet, H., Ruimy, R., & Drancourt, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-27372-7 · Cited by 57
RetractedThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
QuPath: Open source software for digital pathology image analysis
Bankhead, P., Loughrey, M. B., Fernández, J. A., Dombrowski, Y., McArt, D. G., Dunne, P. D., McQuaid, S., Gray, R. T., Murray, L. J., Coleman, H. G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17204-5 · Cited by 8,908
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Self-citationMutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Self-citationUrinary tract infections: epidemiology, mechanisms of infection and treatment options
Flores-Mireles, A. L., Walker, J. N., Caparon, M., & Hultgren, S. J. (2015) · Nature Reviews Microbiology · doi:10.1038/nrmicro3432 · Cited by 4,213
Cited by
Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy
Topalian, S. L., Forde, P. M., Emens, L. A., Yarchoan, M., Smith, K. N., & Pardoll, D. M. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.07.011 · Cited by 317
Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances
Zhao, L., Jin, S., Wang, S., Zhang, Z., Wang, X., Chen, Z., Wang, X., Huang, S., Zhang, D., & Wu, H. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01947-5 · Cited by 218
Pan-cancer single-cell dissection reveals phenotypically distinct B cell subtypes
Yang, Y., Chen, X., Pan, J., Ning, H., Zhang, Y., Bo, Y., Ren, X., Li, J., Qin, S., Wang, D., et al. (2024) · Cell · doi:10.1016/j.cell.2024.06.038 · Cited by 208
T follicular helper cells in cancer
Gutiérrez-Melo, N., & Baumjohann, D. (2023) · Trends in Cancer · doi:10.1016/j.trecan.2022.12.007 · Cited by 209
Derosa, L., Iebba, V., Silva, C. A. C., Piccinno, G., Wu, G., Lordello, L., Routy, B., Zhao, N., Thelemaque, C., Birebent, R., et al. (2024) · Cell · doi:10.1016/j.cell.2024.05.029 · Cited by 198
Self-citation
Metadata
- Authors
- Goubet, A.-G., Lordello, L., Alves Costa Silva, C., Peguillet, I., Gazzano, M., Mbogning-Fonkou, M. D., Thelemaque, C., Lebacle, C., Thibault, C., Audenet, F., Pignot, G., Gravis, G., Helissey, C., Campedel, L., Roupret, M., Xylinas, E., Ouzaid, I., Dubuisson, A., Mazzenga, M., Flament, C., Ly, P., Marty, V., Signolle, N., Sauvat, A., Sbarrato, T., Filahi, M., Davin, C., Haddad, G., Bou Khalil, J., Bleriot, C., Danlos, F.-X., Dunsmore, G., Mulder, K., Silvin, A., Raoult, T., Archambaud, B., Belhechmi, S., Gomperts Boneca, I., Cayet, N., Moya-Nilges, M., Mallet, A., Daillere, R., Rouleau, E., Radulescu, C., Allory, Y., Fieschi, J., Rouanne, M., Ginhoux, F., Le Teuff, G., Derosa, L., Marabelle, A., Van Dorp, J., Van Dijk, N., Van Der Heijden, M. S., Besse, B., Andre, F., Merad, M., Kroemer, G., Scoazec, J.-Y., Zitvogel, L., & Loriot, Y.
- Affiliations
- Inserm (FR)
- 1Gustave Roussy, Villejuif, France.
- 6Urology Department, University Hospital of Bicêtre-Paris Sud-Saclay University, Le Kremlin Bicêtre, Paris, France.
- Université Paris Cité (FR)
- Institut Paoli-Calmettes (FR)
- 10Department of Medical Oncology, Institut Paoli-Calmettes, Aix-Marseille University, CRCM, Marseille, France.
- 11Military Hospital Begin, Saint-Mandé, France.
- Sorbonne Université (FR)
- 13GRC 5 Predictive Onco-Uro, Sorbonne University, Department of Urology, AP-HP, Pitie-Salpetriere Hospital, Paris, France.
- Hôpital Bichat-Claude-Bernard (FR)
- 14Department of Urology, Bichat-Claude Bernard Hospital, Paris University, Paris France.
- 18Veracyte, Marseille, France.
- Institut de Recherche pour le Développement (FR)
- 19Aix-Marseille University, IRD, APHM, MEPHI, Institut Hospitalo-Universitaire Méditerranée Infection, Marseille, France.
- Université Paris-Saclay (FR)
- Institut Gustave Roussy (FR)
- 22Institut Pasteur, Université de Paris, CNRS UMR2001, INSERM U1306, Unité de Biologie et Génétique de la paroi bactérienne, Paris, France.
- Institut Pasteur (FR)
- 23Core Facility Ultrastructural BioImaging Core Facility, Institut Pasteur, Paris France.
- 24EverImmune, Gustave Roussy, Villejuif, France.
- 25Department of Medical Biology and Pathology, Cancer Genetics Laboratory, Gustave Roussy, Villejuif, France.
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- Agency for Science, Technology and Research (SG)
- 31Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, the Netherlands.
- 32Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
- 35The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
- Corresponding author
- Zitvogel, Laurence
- ORCID
- Goubet, Anne-Gaëlle
- Lordello, Leonardo
- Alves Costa Silva, Carolina
- Peguillet, Isabelle
- Gazzano, Marianne
- Mbogning-Fonkou, Maxime Descartes
- Thelemaque, Cassandra
- Lebacle, Cédric
- Thibault, Constance
- Audenet, François
- Pignot, Géraldine
- Gravis, Gwenaelle
- Helissey, Carole
- Campedel, Luca
- Roupret, Morgan
- Xylinas, Evanguelos
- Ouzaid, Idir
- Dubuisson, Agathe
- Mazzenga, Marine
- Flament, Caroline
- Ly, Pierre
- Marty, Virginie
- Signolle, Nicolas
- Sauvat, Allan
- Sbarrato, Thomas
- Filahi, Mounia
- Davin, Caroline
- Haddad, Gabriel
- Bou Khalil, Jacques
- Bleriot, Camille
- Danlos, François-Xavier
- Dunsmore, Garett
- Mulder, Kevin
- Silvin, Aymeric
- Raoult, Thibault
- Archambaud, Baptiste
- Belhechmi, Shaima
- Gomperts Boneca, Ivo
- Cayet, Nadège
- Moya-Nilges, Maryse
- Mallet, Adeline
- Daillere, Romain
- Rouleau, Etienne
- Radulescu, Camelia
- Allory, Yves
- Fieschi, Jacques
- Rouanne, Mathieu
- Ginhoux, Florent
- Le Teuff, Gwénaël
- Derosa, Lisa
- Marabelle, Aurélien
- Van Dorp, Jeroen
- Van Dijk, Nick
- Van Der Heijden, Michiel S.
- Besse, Benjamin
- Andre, Fabrice
- Merad, Miriam
- Kroemer, Guido
- Scoazec, Jean-Yves
- Zitvogel, Laurence
- Loriot, Yohann
- Venue
- Cancer Discovery
- Published
- 2022-08-05
- Volume
- 12
- Issue
- 10
- Pages
- 2280-2307
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W4289936629
- Cited by
- 86
- References
- 85
- Citations by year
- 2026: 18 · 2025: 18 · 2024: 33 · 2023: 16 · 2022: 1
- FWCI
- 7.42
- Type
- journal article
- Language
- en
- Open access
- green
- pure.amsterdamumc.nl
- Licence
- cc-by
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, cc-by)
- Funders
- Fondation pour la Recherche Médicale (FDM201806006036)
- RHU5 (ANR-21-RHUS-0017)
- RHU Torino Lumiere (ANR-16-RHUS-0008)
- ANR (19-CE15-0029-01)
- EU-H2020 (825410)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- muscle-invasive bladder cancer, neoadjuvant pembrolizumab, anti-PD-1 therapy, T follicular helper cells, CXCL13, Escherichia coli, tumor-infiltrating immune cells, tertiary lymphoid structures, PD-L1, treatment response biomarkers, progression-free survival
- MeSH terms
- Immune Checkpoint Inhibitors, Urinary Bladder Neoplasms, Escherichia coli, T-Lymphocytes, Helper-Inducer, Humans, Immunoglobulin G, Muscles, Treatment Outcome, Neoadjuvant Therapy, Chemokine CXCL13, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Escherichia coli –Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer. https://app.cochat.ai/papers/10.1158/2159-8290.cd-22-0201
- The paper
- Goubet, A.-G., Lordello, L., Alves Costa Silva, C., Peguillet, I., Gazzano, M., Mbogning-Fonkou, M. D., Thelemaque, C., Lebacle, C., Thibault, C., Audenet, F., Pignot, G., Gravis, G., Helissey, C., Campedel, L., Roupret, M., Xylinas, E., Ouzaid, I., Dubuisson, A., Mazzenga, M., . . . Loriot, Y. (2022). Escherichia coli –Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-22-0201
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.